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Abstract—The reference standards methyl 3-((2,2-difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)carbamoyl)benzoate 
(5a) and N-(2,2-difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-3-methoxybenzamide (5c), and their corresponding 
desmethylated precursors 3-((2,2-difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)carbamoyl)benzoic acid (6a) and N-(2,2-
difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-3-hydroxybenzamide (6b), were synthesized from 5-amino-2,2-difluoro-
1,3-benzodioxole and 3-substituted benzoic acids in 5 and 6 steps with 33% and 11%, 30% and 7% overall chemical yield, respectively. 
Carbon-11-labeled casein kinase 1 (CK1) inhibitors, [11C]methyl 3-((2,2-difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)carbamoyl)benzoate ([11C]5a) and N-(2,2-difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-3-[11C]methoxybenzamide 
([11C]5c), were prepared from their O-desmethylated precursor 6a or 6b with [11C]CH3OTf through O-[
11C]methylation and isolated by
HPLC combined with SPE in 40-45% radiochemical yield, based on [11C]CO2 and decay corrected to end of bombardment (EOB). The
radiochemical purity was >99%, and the molar activity (MA) at EOB was 370-740 GBq/mol with a total synthesis time of ~40-minutes 
from EOB.  
Keywords: Casein kinase 1 (CK1); Carbon-11-labeled CK1 inhibitors; Radiosynthesis; Positron emission tomography (PET); 
Alzheimer’s disease (AD). 
Casein kinases (CK) are serine/threonine-specific 
enzymes and can be divided two subtypes: casein kinase 
1 (CK1) and casein kinase 2 (CK2).
1
 CK1 contains at
least seven isoforms (, , 1, 2, 3,  and ) expressed 
in eukaryotic organisms, CK1 is involved in various 
cellular processes including membrane trafficking, 
circadian rhythm, cell cycle progression, chromosome 
segregation, apoptosis and cellular differentiation, and 
deregulation of CK1 activity is linked to several 
pathological disorders and diseases like cancer, 
neurodegenerative diseases such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD) and amyotrophic lateral 
sclerosis (ALS), and inflammatory disorders.
2,3
 The
overexpression of CK1 has been described in the human 
AD brain, since CK1 leads to an increase in amyloid- 
(A) peptide production, and also participates in the tau 
fibrillization reaction pathway through phosphorylation 
of tau.
4,5
 CK1 has become an interesting therapeutic
target for AD where an urgent need for effective 
treatment exists, because it opens the door for the use of 
CK1 inhibitors as novel therapeutic approaches for 
AD.
6
 CK1 inhibitors can prevent A formation and
reverse tau hyperphosphorylation in AD, and have been 
used to treat neurodegenerative disorders including 
AD.
4,5,7
  Recently a new series of difluoro-dioxolo-
benzoimidazol-benzamides have been developed as 
potent CK1 inhibitors with nanomolar inhibitory 
activity, these compounds exhibited significant 
inhibitory effects on several tumor cell lines, and their 
in vitro biological data suggested they can be as 
therapeutics for AD as well.
8
AD is a complicated neurodegenerative disease in the 
central nervous system (CNS), the cause of AD remains 
unclear, and so far no any effective treatment strategy is 
approved for preventing, curing and slowing the 
progress of AD.9 To discover more effective treatments, 
more accurate diagnostic tools are crucial to reveal new 
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therapeutic targets.10 New noninvasive diagnostic 
imaging modalities for AD are really needed, both to 
detect and monitor the evolution of this disease, and to 
evaluate the efficacy of treatments.11 Advanced 
biomedical imaging technique positron emission 
tomography (PET) is one of the most widespread 
imaging techniques for AD, and significant progress has 
been made to develop PET agents for two key 
neuropathological substrates of AD: A plaques and tau 
neurofibrillary tangles (NFTs).
12,13
 The representative 
PET A and tau tracers [
11
C]PIB and [
18
F]Amyvid 
([
18
F]AV-45);
14,15
 [
11
C]PBB3 and [
18
F]T807 ([
18
F]AV-
1451)
16,17
 are listed in Figure 1. The development of 
PET imaging probes for in vivo detection of 
Alzheimer’s brains is critical for early and accurate 
diagnosis and for the successful discovery of AD 
therapies.
18
 The success and limitations of A imaging 
and tau imaging have spurred efforts worldwide to 
develop new selective PET tracers for different imaging 
targets. CK1 has emerged as a new molecular imaging 
target of AD,19 but so far no any carbon-11 or fluorine-
18 labeled CK1 inhibitors as PET radiotracers for 
imaging of CK1 were reported. We are interested in the 
development of new PET AD imaging agents, and a 
series of enzyme- or receptor-based PET agents have 
been developed in this laboratory. In our previous work, 
we have targeted the enzyme glycogen synthase kinase-
3 (GSK-3) and developed carbon-11-labeled GSK-3 
inhibitors;
20,21 
and we have also targeted serotonin (5-
hydroxytryptamine) 6 receptor (5-HT6R) and developed  
carbon-11-labeled 5-HT6R antagonists,
22 as PET 
radiotracers for AD imaging (Figure 1). In this ongoing 
study, we first target CK1, which is a novel and 
attractive molecular target for treatment and PET 
imaging of AD.
19
 Here, we report the design, synthesis 
and labeling of carbon-11-labeled CK1 inhibitors, 
[
11
C]methyl 3-((2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)carbamoyl)benzoate ([
11
C]5a) and N-(2,2-difluoro-
5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-3-
[
11
C]methoxybenzamide ([
11
C]5c), as new potential 
PET radiotracers for imaging of AD, for the first time. 
The basic evaluations of the radiotracers including 
lipophilicity and stability are presented as well.     
 
The reference standards methyl 3-((2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)carbamoyl)benzoate (5a) and N-(2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-3-
methoxybenzamide (5c), and their corresponding 
desmethylated precursors 3-((2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)carbamoyl)benzoic acid (6a) and N-(2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-3-
hydroxybenzamide (6b), were synthesized as shown in 
Scheme 1, according to the literature method
8
 with 
modifications. The commercially available starting 
material 5-amino-2,2-difluoro-1,3-benzodioxole was 
treated with acetic anhydride in toluene to obtain 
acetamide 1 in 92% yield. Compound 1 was then 
converted to the intermediate 2 through a concurrent 
nitration and deprotection with nitronium 
tetrafluoroborate (NO2BF4) in 69% yield. In comparison 
with the reported method,
8
 the use of the nitration 
reagent NO2BF4 simplified the reaction steps, 
combining nitration reaction and deprotecting reaction 
into one step, and improved the reaction yield. The nitro 
compound 2 was reduced through hydrogenation using 
H2 and Pd/C as catalyst instead of Raney Nickel 
reported in the literature
8
 to give the intermediate 3 
containing two amino groups, which was subsequently 
reacted with cyanogen bromide to provide the key 
intermediate amino 4 in 82% yield. The catalyst change 
in hydrogenation also improved the yield. Then the 
amino 4 was reacted with several 3-substituted benzoic 
acids under the catalysis of N,N,N′,N′-tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
(HBTU) and N,N-diisopropylethylamine (DIPEA) to 
afford the standard compounds 5a and 5c in 63% and 
21% yield, respectively. A protected benzamide 5b was 
also synthesized in 18% yield. Compound 5a was 
hydrolyzed in methanol solution of KOH to yield its 
acid precursor 6a in 93% yield. Compound 5b was 
converted to O-desmethylated precursor 6b for 
compound 5c through the deprotecting reaction of 
benzyl group employing boron trifluoride diethyl 
etherate (BF3
.
Et2O) and dimethyl sulfide (Me2S) in 65% 
yield.  This deprotective reagent system was found to be 
better than other deprotective reagent system like H2 
and Pd/C, which is easy to result in byproduct formation 
and lower yield. 
 
Synthesis of the target tracers [
11
C]5a and [
11
C]5c is 
indicated in Scheme 2. O-Desmethylated precursor 6a 
or 6b underwent O-[
11
C]methylation
23,24 
using the 
reactive [
11
C]methylating agent [
11
C]methyl triflate 
([
11
C]CH3OTf)
25,26 
in acetonitrile at 80 °C under basic 
conditions (2 N NaOH). The product was isolated by 
semi-preparative reverse-phase (RP) high performance 
liquid chromatography (HPLC) with a C-18 column,
 
and then concentrated by solid-phase extraction 
(SPE)
27,28
 with a disposable C-18 Light Sep-Pak 
cartridge to produce the corresponding pure 
radiolabeled compound [
11
C]5a or [
11
C]5c in 40-45%  
radiochemical yield, decay corrected to end of 
bombardment (EOB), based on [
11
C]CO2. 
 
The radiosynthesis was performed in a home-built 
automated multi-purpose [
11
C]-radiosynthesis 
module.
29-31
 Our radiosynthesis module facilitated the 
overall design of the reaction, purification and 
reformulation capabilities in a fashion suitable for 
  
 
adaptation to preparation of human doses. The 
radiosynthesis includes three stages: 1) labeling 
reaction; 2) purification; and 3) formulation. More 
reactive [
11
C]CH3OTf, instead of commonly used 
[
11
C]methyl iodide ([
11
C]CH3I),
32
 was used in O-
[
11
C]methylation to improve radiochemical yield of 
[
11
C]5a and [
11
C]5c. The Eckert & Ziegler Modular Lab 
C-11 Methyl Iodide/Triflate module in our facility can 
produce [
11
C]methylating agent either [
11
C]CH3OTf or 
[
11
C]CH3I ([
11
C]CH3Br passed through a NaI column). 
The direct comparison between [
11
C]CH3OTf and 
[
11
C]CH3I confirmed the result that the labeling yield 
was improved from 30-35% to 40-45%. The labeling 
reaction was conducted using a V-vial method. Addition 
of aqueous NaHCO3 to quench the radiolabeling 
reaction and to dilute the radiolabeling mixture prior to 
the injection onto the semi-preparative HPLC column 
for purification gave better separation of [
11
C]5a or 
[
11
C]5c from its O-desmethylated precursor 6a or 6b. 
Both Sep-Pak trap/release and rotatory evaporation are 
available for formulation in our multi-purpose [
11
C]-
radiosynthesis module, and we used Sep-Pak method 
instead of rotatory evaporation for formulation to 
improve the chemical purity of radiolabeled product 
[
11
C]5a or [
11
C]5c. The direct comparison between Sep-
Pak method and rotatory evaporation confirmed the 
result that the chemical purity of radiolabeled product 
was improved from <90% to >90%. In addition, a C18 
Light Sep-Pak to replace a C18 Plus Sep-Pak allowed 
final product formulation with ≤5% ethanol.
33
 Overall, 
it took ~40 min for synthesis, purification and dose 
formulation.    
 
Our module is designed to allow in-process 
measurement of [
11
C]-tracer molar activity (MA, 
GBq/mol at EOB) using a radiation detector with a UV 
detector at the outlet of the HPLC-portion of the 
system.
31
 In the HPLC chromatogram, peak analysis of 
the chromatographic data utilized PeakSimple software 
(SRI Instruments, Las Vegas, NV). Immediately 
following elution of the product peak, the 
chromatographic data are exported to PeakSimple 
readable files, and the area of the radioactivity peak is 
converted to GBq - mCi at EOB by comparison to a 
reference calibration curve previously constructed using 
the same detector, loop column, mobile phase and flow 
rate. The mass peak from the UV chromatogram 
(without decay correction) is similarly compared to a 
standard curve made at the same UV wavelength, 
mobile phase and flow rate. Simple division of the total 
EOB radioactivity peak (in GBq - mCi) by the total 
mass peak (in nmoles) gives specific activity at EOB in 
GBq - Ci/mol. For the reported syntheses, product MA 
was in a range of 370-740 GBq/mol at EOB. The 
factors that affect the EOB MA significantly to lead to 
such a wide range have been discussed in our previous 
works.
34-36
 The general methods to increase SA have 
been described as well, and the SA of our [
11
C]-tracers 
is significantly improved.
34-36
 The ‘wide range’ of MA 
we reported is for the same [
11
C]-tracer produced in 
different days, because very different [
11
C]-target and 
[
11
C]-radiosynthesis unit situations would make MA in 
a wide range. For a [
11
C]-tracer produced in the same 
day, the MA of the same tracer in different production 
runs will be in a small range, because [
11
C]-target and 
[
11
C]-radiosynthesis unit would not be much different in 
the same day. Likewise, the methods to minimize such 
wide range of MA from practice perspective have been 
provided in our previous works.
34-36
 At the end of 
synthesis (EOS), the MA of [
11
C]-tracer was determined 
again by analytical RP HPLC, calculated, decay 
corrected to EOB, and based on [
11
C]CO2, which was in 
agreement with the ‘on line’ determined value. In this 
work, semi-preparative HPLC was used for purification, 
thus the MA of [
11
C]-tracer was assessed by both semi-
preparative HPLC (during synthesis) and analytical 
HPLC (EOS). 
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.
37
 The chemical purity 
of the precursor and reference standard was >93%. The 
radiochemical purity of the target tracer was >99% 
determined by radio-HPLC through -ray (PIN diode) 
flow detector, and the chemical purity of the target 
tracer was >90% determined by reversed-phase HPLC 
through UV flow detector.   
 
 
Figure 1. PET radiotracers for imaging of AD. 
 
  
 
 
Scheme 1. Synthesis of reference standards 5a; 5c and O-desmethylated 
precursors 6a; 6b. Reaction reagents, conditions and yields: (i) acetic 
anhydride, toluene, 100 °C, 92%. (ii) NO2BF4, CH2Cl2, 69%. (iii) 
hydrogen, Pd/C, methanol; (iv) cyanogen bromide, methanol, room 
temperature (RT), 40 h, 82%. (v) 3-substitutent-benzoic acid, HBTU, 
DIPEA, 18-63%. (vi) for 6a, KOH, methanol, 93%; for 6b, Me2S, 
BF3
.Et2O, CH2Cl2, 65%. 
 
 
Scheme 2. Synthesis of target tracers [11C]5a and [11C]5c. Reaction 
reagents, conditions and yields: (i) [11C]CH3OTf, CH3CN, 2 N NaOH, 80 
°C, 3 min; HPLC-SPE, 40-45%.  
 
Table 1. Log P and CLog P values of carbon-11-labeled 
CK1 inhibitors [
11
C]5a and [
11
C]5c in comparison with 
[
11
C]PIB, [
18
F]Amyvid, [
11
C]PBB3 and [
18
F]T807. 
Compound Log P CLog P 
[
11
C]5a 3.60 5.09 
[
11
C]5c 3.66 5.12 
[
11
C]PIB 3.41 3.99 
[
18
F]Amyvid 3.16 3.91 
[
11
C]PBB3 4.09 4.05 
[
18
F]T807 2.25 3.18 
   
The octanol-water partition coefficient (commonly 
expressed as Log P) is an important physical parameter 
directly correlated with the biological activities of a 
wide variety of organic compounds.
36,38
 Log P provides 
an assessment of lipophilicity that often correlates with 
a compound’s ability to penetrate the blood brain barrier 
(BBB). Log P can be determined experimentally by 
liquid-liquid extraction and by HPLC
38
 and can also be 
theoretically calculated from parameters related to the 
structure of molecules. We obtained Log P and 
calculated Log P (CLog P) values of carbon-11-labeled 
CK1 inhibitors [
11
C]5a and [
11
C]5c in comparison with 
[
11
C]PIB, [
18
F]Amyvid, [
11
C]PBB3 and [
18
F]T807 
(Figure 1) from ChemDraw Professional 15.1 
(ChemOffice), and the data are listed in Table 1. Log P 
data of [
11
C]5a and [
11
C]5c (3.60 - 3.66) are in the range 
of Log P data of [
11
C]PIB, [
18
F]Amyvid, [
11
C]PBB3 and 
[
18
F]T807 (2.25 – 4.09), which are PET AD imaging 
agents in clinical evaluation. These data suggest [
11
C]5a 
and [
11
C]5c have appropriate lipophilicity to pass the 
BBB for brain uptake.  
 
The stability of the labeled tracers [
11
C]5a and [
11
C]5c 
was evaluated by analytical HPLC from EOS up to 3 h, 
one injection of the tracer solution in EtOH/saline onto 
HPLC column per hour. The HPLC chromatograms 
showed [
11
C]5a and [
11
C]5c were stable without 
decomposition.    
 
The experimental details and characterization data for 
compounds 1-6 and for the tracers [
11
C]5a and [
11
C]5c 
are given.
39 
 
 
In summary, synthetic routes with moderate to high 
yields have been developed to produce difluoro-
dioxolo-benzoimidazol-benzamides including reference 
standards 5a and 5c, and O-desmethylated precursors 6a 
and 6b, and carbon-11-labeled difluoro-dioxolo-
benzoimidazol-benzamides target tracers [
11
C]5a and 
[
11
C]5c. The radiosynthesis employed [
11
C]CH3OTf for 
O-[
11
C]methylation at O-desmethylated precursor, 
followed by product purification and isolation using a 
semi-preparative RP HPLC combined with SPE. 
[
11
C]5a and [
11
C]5c were obtained in high 
radiochemical yield, radiochemical purity and chemical 
purity, with a reasonable short overall synthesis time, 
and high molar activity. This will facilitate studies to 
evaluate carbon-11-labeled CK1 inhibitors [
11
C]5a and 
[
11
C]5c as new candidate PET radiotracers for imaging 
of AD.      
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 Melting points were determined on WRR 
apparatus and were uncorrected. 
1
H and 
13
C NMR 
spectra were recorded on a Bruker Avance II 500 
MHz NMR Fourier transform spectrometer at 500 and 
125 MHz, respectively. Chemical shifts (δ) are 
reported in parts per million (ppm) relative to an 
internal standard tetramethylsilane (TMS,  0.0) (1H 
NMR) and to the solvent signal (
13
C NMR), and 
coupling constants (J) are reported in hertz (Hz). 
Liquid chromatography-mass spectra (LC-MS) 
analysis was performed on an Agilent system, 
consisting of an 1100 series HPLC connected to a 
diode array detector and a 1946D mass spectrometer 
configured for positive-ion/negative-ion electrospray 
ionization. The high resolution mass spectra (HRMS) 
were obtained using a Waters/Micromass LCT Classic 
spectrometer. Chromatographic solvent proportions 
are indicated as volume: volume ratio. Thin-layer 
chromatography (TLC) was run using Analtech silica 
gel GF uniplates (5  10 cm2).  Plates were visualized 
under UV light. Normal phase flash column 
chromatography was carried out on EM Science silica 
gel 60 (230-400 mesh) with a forced flow of the 
indicated solvent system in the proportions described 
below. All moisture- and air-sensitive reactions were 
performed under a positive pressure of nitrogen 
maintained by a direct line from a nitrogen source. 
Analytical RP HPLC was performed using a Prodigy 
(Phenomenex) 5 m C-18 column, 4.6  250 mm; 
mobile phase 60%CH3CN/40% H2O; flow rate 1.3 
mL/min; UV (254 nm) and -ray (PIN diode) flow 
detectors. Semi-preparative RP HPLC was performed 
using a Prodigy (Phenomenex) 5 m C-18 column, 10 
 250 mm; mobile phase 60%CH3CN/40%H2O; flow 
rate 5 mL/min; UV (254 nm) and -ray (PIN diode) 
flow detectors. C18 Light Sep-Pak cartridges were 
obtained from Waters Corporation (Milford, MA).  
Sterile Millex-FG 0.2 m filter units were obtained 
from Millipore Corporation (Bedford, MA).  
(b). N-(2,2-Difluorobenzo[d][1,3]dioxol-5-
yl)acetamide (1): A solution of 5-amino-2,2-difluoro-
1,3-benzodioxole (14.4 g, 83.2 mmol) in dry toluene 
(230 mL) and acetic anhydride (9.76 g, 95.7 mmol, 
1.15 equiv) was stirred at 100 °C for 3 h. The solvent 
was removed under reduced pressure, then the crude 
product was dissolved in 80 mL of methanol to 
remove traces of acetic anhydride. The solvent was 
subsequently evaporated. The crude product was 
recrystallized from toluene, and the resulting product 
was filtered off and dried to give a beige crystal 1 
(16.5 g, 92%), Rf = 0.25 (1:2 EtOAc/Hexanes), mp 
140-142 °C. 
1
H NMR (DMSO-d6):  2.05 (s, 3H, 
CH3), 7.21 (dd, J = 2.0, 8.5 Hz, 1H, Ph-H), 7.31 (d, J 
= 8.5 Hz, 1H, Ph-H), 7.75 (d, J = 2.0 Hz, 1H, Ph-H), 
10.14 (s, 1H, NH). MS (ESI): 216 ([M+H]
+
, 100%); 
MS (ESI): 214 ([M-H]
-
, 100%). 
(c). 2,2-Difluoro-6-nitrobenzo[d][1,3]dioxol-5-amine 
(2): Compound 1 (15.6 g, 72.5 mmol) was dissolved 
in dichloromethane (250 mL). To the resulting 
mixture, nitronium tetrafluoroborate solution (174 mL, 
0.5 M in sulfolane) was added dropwise at 0 °C. After 
addition, the reaction mixture was allowed to RT and 
stirred for 24 h. Then the reaction mixture was 
evaporated to remove dichloromethane, and the 
resulting mixture was added with water, extracted 
  
 
with EtOAc, washed with water two times, and dried 
over Na2SO4. The mixture was filtered, and filtrate 
was evaporated in vacuo. The resultant residue was 
purified by column chromatography on silica gel with 
eluent (2:98 to 20:80 EtOAc/hexanes) to give a light 
beige solid 2 (10.9 g, 69%), Rf = 0.73 (CH2Cl2), mp 
138-140 °C. 
1
H NMR (DMSO-d6):  6.94 (s, 1H, Ph-
H), 7.79 (s, 2H, NH2), 7.94 (s, 1H, Ph-H). MS (ESI): 
219 ([M+H]
+
, 3%); MS (ESI): 217 ([M-H]
-
, 100%). 
(d). 2,2-Difluorobenzo[d][1,3]dioxole-5,6-diamine 
(3): Compound 2 (5.0 g, 22.9 mmol)  was dissolved in 
methanol  (120 mL) and hydrogenated under hydrogen 
atmosphere (55 psi) with Pd/C (300-500 mg) as a 
catalyst for 4 h. The reaction mixture was filtered over 
Celite 545 and washed with methanol. The solvent 
was evaporated in vacuo to obtain a purple solid 3, 
which was directly used for next step without further 
purification because this compound was unstable on 
silica gel column. Rf = 0.34 (CH2Cl2). MS (ESI): 189 
([M+H]
+
, 100%); MS (ESI): 187 ([M-H]
-
, 45%). 
(e). 2,2-Difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
d]imidazol-6-amine (4): The crude product 3 (0.94 g, 
5.0 mmol) was dissolved in dry methanol, cyanogen 
bromide (795 mg, 7.5 mmol) was added. The reaction 
mixture was stirred at RT for 40 h. The reaction 
mixture was concentrated, and the residue was 
purified by column chromatography on silica gel with 
eluent (2:98 to 10:90 MeOH/CH2Cl2) to give a brown 
solid 4 (875 mg, 82%), Rf = 0.27 (1:19 
MeOH/CH2Cl2), mp 135-137 °C.
 1
H NMR (DMSO-
d6):  7.35 (s, 2H, Ph-H), 7.66 (s, 2H, NH2). MS 
(ESI): 214 ([M+H]
+
, 100%); MS (ESI): 212 ([M-H]
-
, 
70%). 
(f). General procedure for synthesis of compounds 5a-
c: Compound 4 (213 mg, 1.0 mmol) and 3-substituted 
benzoic acid (1.0 mmol) were dissolved in 10 mL of 
dry N,N-dimethylformamide (DMF), HBTU (417 mg, 
1.1 mmol) and DIPEA (258 mg, 2.0 mmol) were 
added, and the reaction mixture was stirred at RT for 
18 h. Then the reaction mixture was concentrated in 
vacuo. The residue was washed with water, and dried 
in air to give crude product, which was purified by 
column chromatography on silica gel with eluent (1:99 
to 5:95 MeOH/CH2Cl2) to afford a white solid 5. 
Methyl 3-((2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)carbamoyl)benzoate (5a): Yield 63%, Rf = 0.52 
(1:13 MeOH/CH2Cl2), mp 252-254 °C. 
1
H NMR 
(acetone-d6):  3.90 (s, 3H, OCH3), 7.35 (s, 2H, Ph-
H), 7.71 (t, J = 8.0 Hz, 1H, Ph-H), 8.23 (dt, J = 1.5, 
8.0 Hz, 1H, Ph-H), 8.39 (dt, J = 1.5, 8.0 Hz, 1H, Ph-
H), 8.72 (t, J = 1.5 Hz, 1H, Ph-H). MS (ESI): 376 
([M+H]
+
, 25%); MS (ESI): 374 ([M-H]
-
, 100%).  
3-(Benzyloxy)-N-(2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)benzamide (5b): Yield 18%, Rf = 0.67 (1:9 
MeOH/CH2Cl2), mp 221-223 °C. 
1
H NMR (acetone-
d6):  7.30-7.32 (m, 3H, Ph-H), 7.33 (dt, J = 2.0, 7.0 
Hz, 1H, Ph-H),  7.39 (tt, J = 1.5, 8.5 Hz, 2H, Ph-H), 
7.45-7.51 (m, 3H, Ph-H), 7.76 (td, J = 1.0, 8.0 Hz, 1H, 
Ph-H), 7.80 (t, J = 2.0 Hz, 1H, Ph-H), 11.80 (br s, 1H, 
NH). MS (ESI): 424 ([M+H]
+
, 9%); MS (ESI): 422 
([M-H]
-
, 100%).  
N-(2,2-Difluoro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
d]imidazol-6-yl)-3-methoxybenzamide (5c):  Yield 
21%, Rf = 0.54 (1:13 MeOH/CH2Cl2), mp 241-243 °C. 
1
H NMR (DMSO-d6):  3.87 (s, 3H, OCH3), 7.21 
(ddd, J = 1.0, 2.5, 8.0 Hz, 1H, Ph-H), 7.31 -7.33 (br s, 
2H, Ph-H), 7.47 (t, J = 8.0 Hz, 1H, Ph-H), 7.70 (t, J = 
7.0 Hz, 1H, Ph-H), 7.73 (dd, J = 1.0, 1.5 Hz, 1H, Ph-
H), 7.75 (td, J = 1.0, 1.5 Hz, 1H, Ph-H), 11.80 (br s, 
1H, NH). MS (ESI): 348 ([M+H]
+
, 25%); MS (ESI): 
346 ([M-H]
-
, 100%).  
(g). 3-((2,2-Difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)carbamoyl)benzoic acid (6a): Potassium hydroxide 
(KOH, 0.5 g, 7.6 mmol) was added into the solution of 
compound 5a (375 mg, 1.0 mmol) in methanol (20 
mL). The reaction mixture was stirred at RT for 15 h. 
Then the reaction mixture was concentrated in vacuo, 
and HCl (1 N) was added to adjust pH to 7. The 
resulting precipitate was filtered, washed with cold 
water, dried in air to give a white solid 6a (336 mg, 
93%), Rf = 0.20 (1:9 MeOH/CH2Cl2), mp > 310 °C. 
1
H 
NMR (DMSO-d6):  7.48 (s, 2H, Ph-H), 7.63 (t, J = 
7.5 Hz, 1H, Ph-H), 8.16 (d, J = 7.5 Hz, 1H, Ph-H), 
8.26 (d, J =7.5 Hz, 1H, Ph-H), 12.55 (br s, 1H, OH). 
MS (ESI): 362 ([M+H]
+
, 15%); MS (ESI): 360 ([M-
H]
-
, 25%). HRMS (ESI): calcd for C16H10N3O5F2, 
362.0589 ([M+H]
+
), found 362.0579.  
(h). N-(2,2-Difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-3-
hydroxybenzamide (6b): BF3
.
OEt2 (0.8 mL) and Me2S 
(1.0 mL) were added to a solution of compound 5b 
(212 mg, 0.5 mmol) in dichloromethane (20 mL) at 0 
°C. The resulting mixture was stirred at 0 °C for 2 h 
and at RT for 2 h. Then the reaction mixture was 
evaporated to dryness in vacuo. The residue was 
suspended in a mixture of aqueous NaHCO3, and 
extracted with EtOAc (3 × 80 mL). The combined 
organic layers were washed with brine, dried over 
Na2SO4, and concentrated. The residue was purified 
by column chromatography on silica gel with eluent 
(2:98 MeOH/CH2Cl2) to give a white solid 6b (109 
mg, 65%), Rf  = 0.50 (7:93 MeOH/CH2Cl2), mp 249-
251 °C. 
1
H NMR (acetone-d6):  7.12 (ddd, J = 0.5, 
2.5, 8.5 Hz, 1H, Ph-H), 7.30 (br s, 2H, Ph-H), 7.38 (t, 
J = 7.0 Hz, 1H, Ph-H), 7.65 (ddd, J = 0.5, 2.5, 8.5 Hz, 
1H, Ph-H), 11.77 (br s, 1H, OH). 
13
C NMR (acetone-
d6):  113.44, 115.54, 115.79, 118.49, 119.94, 120.55, 
130.76, 135.39, 140.32, 143.37, 148.67, 158.61, 
167.45. MS (ESI): 334 ([M+H]
+
, 60%); MS (ESI): 
332 ([M-H]
-
, 100%). HRMS (ESI): calcd for 
C15H10N3O4F2, 334.0639 ([M+H]
+
), found 334.0625.  
(i) [
11
C]methyl 3-((2,2-difluoro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-
yl)carbamoyl)benzoate ([
11
C]5a) and N-(2,2-difluoro-
5H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]imidazol-6-yl)-
  
 
3-[
11
C]methoxybenzamide ([
11
C]5c): [
11
C]CO2 was 
produced by the 
14
N(p,)11C nuclear reaction in the 
small volume (9.5 cm
3
) aluminum gas target provided 
with the Siemens RDS-111 Eclipse cyclotron. The 
target gas consisted of 1% oxygen in nitrogen 
purchased as a specialty gas from Praxair, 
Indianapolis, IN. Typical irradiations used for the 
development were 58 A beam current and 20 min on 
target. The production run produced approximately 
37.0 GBq of [
11
C]CO2 at EOB. The precursor 6a or 6b 
(0.1-0.3 mg) was dissolved in CH3CN (300 L). To 
this solution was added aqueous NaOH (2 N, 2 L). 
The mixture was transferred to a small reaction vial. 
No-carrier-added (high molar activity) [
11
C]CH3OTf 
that was produced by the gas-phase production 
method
26
 within 12 min from [
11
C]CO2 through 
[
11
C]CH4 and [
11
C]CH3Br with AgOTf column was 
passed into the reaction vial at RT until radioactivity 
reached a maximum (2 min), and then the reaction vial 
was isolated and heated at 80 C for 3 min. The 
contents of the reaction vial were diluted with aqueous 
NaHCO3 (0.1 M, 1 mL). The reaction vial was 
connected to a 3-mL HPLC injection loop. The 
labeled product mixture solution was injected onto the 
semi-preparative HPLC column for purification. The 
product [
11
C]5a or [
11
C]5c fraction was collected in a 
recovery vial containing 30 mL water. The diluted 
tracer solution was then passed through a C-18 Light 
Sep-Pak cartridge, and washed with water (3 × 10 
mL). The cartridge was eluted with EtOH (3  0.4 
mL) to release the labeled product, followed by saline 
(10-11 mL). The eluted product was then sterile-
filtered through a Millex-FG 0.2 m membrane into a 
sterile vial. Total radioactivity was assayed and total 
volume (10-11 mL) was noted for tracer dose 
dispensing. The overall synthesis time including 
HPLC-SPE purification and reformulation was ~40 
min from EOB. The decay corrected radiochemical 
yield was 40-45%. Retention times in the analytical 
HPLC system were: tR 6a = 4.77 min, tR 5a = 6.13 
min, tR [
11
C]5a = 6.21 min; and tR 6b = 4.82 min, tR 5c 
= 6.34 min, tR [
11
C]5c = 6.41 min. Retention times in 
the preparative HPLC system were: tR 6a = 5.85 min, 
tR 5a = 10.02 min, tR [
11
C]5a = 10.18 min; and tR 6b = 
6.05 min, tR 5c = 10.23 min, tR [
11
C]5c = 10.38 min. 
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 New carbon-11-labeled CK1 inhibitors were 
synthesized. 
 A fully automated multi-purpose [11C]-
radiosynthesis module was built up. 
 A semi-preparative RP HPLC-SPE technique 
was employed in radiosynthesis. 
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